REPUBLIC OF THE SUDAN - PowerPoint PPT Presentation

Loading...

PPT – REPUBLIC OF THE SUDAN PowerPoint presentation | free to view - id: 71243-ZDc1Z



Loading


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation
Title:

REPUBLIC OF THE SUDAN

Description:

Research Activities conducted in Sudan for assessments of ... Nyala. 50% 22. Dec. 1999 Jan.2000. Gezira. Medani. 41.2% 17. Dec. 1999 Jan.2000. Blue Nile ... – PowerPoint PPT presentation

Number of Views:70
Avg rating:3.0/5.0
Slides: 32
Provided by: yasainab
Category:
Tags: republic | sudan | the | nyala

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: REPUBLIC OF THE SUDAN


1
REPUBLIC OF THE SUDAN
2
Inter Country workshop on monitoring Therapeutic
Efficiency of Antimalarial Drugs Sanaa Rep. of
Yemen 21 25 April 2002. Research Activities
conducted in Sudan for assessments of
antimalarial resistance county experience in
establishing sentinel sites surveillance for
monitering therapeutic efficiency of antimalarial
drugs using WHO modified protocol. Dr. Abdel
latif M. Salih Q. A. of Diag. And Treatment
NMA Dr. Abu Algasim Abdel Rahim Omer Director
of Malaria Unit South Kordofan
3
Introduction- Sudan is the largest country in
Africa and the Middle East, with an area of 2.7
million km2 and 30 million population, 60 are
rural, 10 nomads and 30 are urban. The country
is divided into 26 States, 112 Provinces and 700
Localities. Malaria is the major health problem
in the country. Annual cases 7.5 million annual
deaths 35000. The whole population is at risk of
developing the disease, generally two main
epidemiological situation are identified stable
(perennial transmission and unstable with
epidemic prone (constitutes gt 65 of
population). The main vector is A. Arabiensis
and Dominant parasite is P.F. gt 90 followed by
P.V. which is now increasing specially in the
east of Sudan.
4
  • Endemicity of Malaria-
  • Going from North to the South of Sudan could be
    divided into-
  • Meso endemic.
  • Hypo endemic.
  • Hyper endemic.
  • Holo endemic.

5
  • Now RBM programme is adopted in Sudan. The
    programme is built on partnership.
  • Main strategies are-
  • Early diagnosis and prompt treatment.
  • Multiple preventive measures inducing personal
    protection.
  • Early detection and containment of epidemics,
  • Focused researches.
  • RBM is the responsibility of NMA at the Federal
    level and malaria units at State levels.

6
NMSLA
L. Cor. M. Con. S. Con


7
Malaria treatment- Malaria is recognized when
there is fever with ring stage in peripheral
blood. i.e. the clinical picture is confirmed
by laboratory examination RDTs are now
introduced but in a narrow scale. Malaria
is differentiated into simple and complicated
malaria.
8
  • National Protocol for Treatment of Malaria-
  • Two workshops were held in Sudan on this topic,
    as a result the National Malaria Protocol was
    agreed upon. According to the National Protocol
    the disease is treated as follows-
  • Simple Malaria (Specific treatment)-
  • 1st line treatment is Chloroquine (total dose for
    adults is 1500mg tab or 7 injection of 200mg.
    Children according to body weight 25mg/kg.
  • 2nd line is Fansidar (S/P) or oral Quinine in
    case of pregnancy.
  • 3rd line treatment is either mefloquine or oral
    Quinine
  • Severe malaria is treated specifically with
    Quinine or Artemether injections.
  • There are other antimalarials which are not
    included in the Protocol but still they are
  • prescribed by some practioners e.g. Halofantrine.
  • In practice resistance to chloroquine is observed
    by practioners. Resistance to other antimalraials
    is doughtfull. Chloroquine is still the 1st line
    drug in common use.
  • The National Protocol is to be revised and the
    1st line of treatment will be changed according
    to studies on Plasmodium sensibility to
    chloroquine.

9
Drug Resistance- Drug resistance of malaria
parasites has been defined as the ability of a
parasite strain to multiply and/ or survive in
the presence of concentration of a drug that
normally destroys parasites of the same species
or prevent their multiplication (Bruce-Chawat, L.
J. ed (1981). This definition has been further
qualified into relative resistance, i.e. yielding
to increased, doses of the drug tolerated by the
host, or complete resistance, i.e withstanding
maximum doses tolerated by the host. Nowadays the
common use of the term drug resistance related to
complete resistance and is based on
parasitological features. When speaking of
resistance to antimalarials, attention is
generally focused on P.falciparum, since failure
or success of medication may determine the
patients survival. This is rarely so in
infections with the other human-pathogenic
Plasmodium species.
10
Drug resistance in Sudan (1)- In 1978, the
chloroquine sensitivity of P.falciparum was
studied in two areas of Sudan. In the Gezria,
99.4 of the patients treated responded
completely to the drug. Two patients (0.4) and
one patient (0.2) showed, respectively RI and
RII responses (Abdel Hamid Sayed Omer). In the
district of Sennar, the results of in vivo test
showed parasite resistant at the RI level only,
but the mean clearance time of trophozoies from
the blood was higher than for strains found in
many other areas of tropical Africa. (KouzneTsov,
et al 1980). In vivo assessment of the
sensitivity of P.falciparum to chloroquine was
carried out in 63 patients in eastern Sudan
Standard triple dose therapy with chloroquine
(25mg base/Kg body wt) failed in curing 30
patients, all grades of resistance were
demonstrated in the study in the area. (Saeed-BO
et al. 1990). In the 1992 study reports on
chloroquine resistance of P.falciparum among
Sudanese children (6 month to 16 years) living at
Wad Medani, Central Sudan. All levels of
resistance response were confirmed (Ibrahim-AM
et al 1992).
11
  • Drug resistance in Sudan (2)-
  • Of 56 children lt 5 years old seen between
    December 1994 and January 1995 in Waat, Uper Nile
    province, who had pure P.falciparum malaria, 50
    were followed up for 14 days after treatment with
    chloroquine (10mg/kg on day 1 and 2, 5mg/Kg on
    day 3). Three were still positive on day 7 (RII
    resistance), and 2 others who were negative on
    day 3 and 7 became positive again on day 14 (RI
    resistance). (Guthman-PJ et al, 1996).
  • Fansidar
  • Resistance to S/P has been reported in Central
    Sudan (Ibrahim et al 1991).
  • But in vitro study in Eastern Sudan showed 100
    sensitivity (Khalil 1995).
  • Quinine-
  • In vitro resistance of P.falciparum to quinine
    was also reported in Eastern part of Sudan
    (Khalil 1995).
  • In practice Quinine and Fansidar are still
    effective drugs. Chloroquine is still prescribed
    as the 1st line treatment for un complicated
    malaria.

12
  • Research activities for assessment of
    antimalarial resistance-
  • Some researches are conducted by Department of
    Biochemistry (U. of K.) (in vivo test) for
    sensitivity of P.F to Chloroquine/ Fansidar and
    Quinine in New Halfa in the East of the Sudan
    (the attached study).
  • The Study conclusion-
  • Chloroqunine resistance is worsening.
  • Quinine resistance is emerging.
  • Fansidar is fully effective.
  • Other researches are conducted in Gezira
    University
  • PhD research on chlororquine and fansidar
    assessment outcome in the treatment of un
    complicated malaria by Mr. Bakri Yousif. Other
    researches are conducted by the same researcher
    are
  • The in vivo and in vitro sensitivity of quinine
    in the treatment of severe malaria in Madani
    teaching Hospital.
  • The therapeutic efficacy of chloroquine
    primaquine to prevent relapse of P. vivax in
    Gezira.
  • A randomised trial of oral artemether plus
    chloroquine in the treatment of uncomplicated P.
    F. malaria in Central Sudan.
  • Researches to obtain MD from U of G by 3
    malariologists on efficacy of antimalarials in
    Gadarif, Madani and Sinnar areas

13
Experience in establishing sentinel sites using
WHO protocol- A workshop was organized in BNTRI
in Gezira in 1997 to develop a system for
monitoring therapeutic efficacy of antimalarial
drugs against P.F infections in Sudan. There
are no permanent sentinel sites. Studies are
carried out in different parts of the country
with a hope to develop a sensitivity map of P.F
to antimalarial drugs, chloroquine is targeted
mainly at the present. 18 sentential sites are
suggested.
14
  • The ongoing studies are at the following sites-
  • Northern State.
  • Khartoum State.
  • Gezria State.
  • White Nile State.
  • Nourth Kordofan State.
  • Blue Nile State.

15
Summary of results of some studies carried out
under NMA supervision
16
  • Problems in establishing sentinel sites-
  • Lack of training.
  • Lack of close supportive supervision.
  • Unstable staff.
  • Poor incentives (for both team work and patients).

17
Modified WHO Protocol for Assessment of
Therapeutic Efficacy of Chloroquine for
Uncomplicated Falciparum Malaria (In Vivo Test
Guidelines)
18
Introduction Malaria is the first public health
problem in Sudan. Chloroquine is the first line
drug for treatment since very early time. Many
studies targeting Chloroquine efficacy were done
with different results. All proved that there is
some degree of resistance. For the National and
State Malaria Administration (NMA SMA) there is
high need for reassessing the efficacy. The
modified standardized in vivo test for testing
the response of Plasmodium falciparum to drugs is
used. The test follows a set of criteria for the
selection of patients, the administration of
standard treatment regimens of the appropriate
drug, and daily parasitological blood
examination. In order to assess the therapeutic
efficacy of routine treatment regimens, the test
should be carried out only in persons suffering
from clinically manifested, microscopically
confirmed falciparum malaria. The test system
expected to provide information required for
guiding drug policies and for monitoring the
efficacy of antimalarial drugs overtime.
19
  • Objective (1)-
  • To assess the efficacy of Chloroquine as a first
    line drug for treatment of uncomplicated
    falciparum malaria.
  • Materials and Methods
  • Study type
  • This is a cross-sectional community-based study
  • Study area
  • To avoid selection bias the following should be
    considered
  • The study should be carried out in an isolated
    area, preferably in a rural setting. The rural
    health center or dispensaries are the most
    suitable sites. An outpatient department (OPD) of
    a rural hospital comes second and then the urban
    health center or OPD of teaching or urban
    hospital.
  • The chosen health facilities are better to be at
    a relatively short distance i.e in one district.
  • The study team should avoid awareness campaign
    and should select a health facility, which
    usually receive at least 15-20 febrile patients/
    day.
  • Efforts should be made to include all febrile
    patients in the area.

20
Objective (2)- Study population The study
population comprises all attendance whose illness
proved to be uncomplicated falciparum malaria
clinically (febrile) and microscopically. Sample
size- The sample size varies depending on the
financial, institutional and personnel resources
available. Sample size can be determined by using
LQAS (Lot Quality Assurance Sampling). According
to this method the National Malaria
Administration will look seriously in any study
based on a sample size not less than 100
patients i.e to negotiate changing Chloroquine as
a first line drug. This sample size corresponds
with an upper threshold level of clinical failure
(Po) equal to 25 and a lower level (Pa) of 0.75
and with the power of test equal to 80.
21
  • Sampling
  • The selection of the required sample size should
    be based on the following criteria
  • Inclusion criteria
  • Age above 6 months
  • Mono-infection with P. falciparum
  • Parasite count of 500 100.000/ cumm (asexual
    stages).
  • Presence of fever or history of fever during the
    previous 48 hours
  • Ability to come for the stipulated follow-up
    visits.
  • Easy access to health facility.
  • Informed consent

22
  • Exclusion criteria
  • Presence of severe complicated malaria or general
    danger signs-
  • Not able to drink or breastfeed
  • Vomiting everything
  • Recent history of convulsions
  • Lethargic or unconscious state
  • Unable to sit or stand up
  • Axillary temperature gt39.5
  • Pregnancy
  • Febrile diseases other than malaria

23
  • The test system
  • Test Schedule (See annex I)
  • A pre-treatment assessment, which includes
    recording essential patient information, clinical
    assessment including body temperature and
    parasitaemia.
  • The body weight should be taken at Day 0 and then
    the supervised treatment with the recommended
    drug and dose and treatment schedule will be
    given (Annex IV).
  • If the patient meets all the required criteria,
    the patient is recorded in a logbook and entered
    in the record form.
  • Clinical assessment with measuring of body
    temperature is to be done on Days 1, 2, 3, 7 and
    14.
  • Parasitological examination on Days 0, 3, 7 and
    14.

24
  • Follow up procedure
  • The representativeness of the study diminishes
    with an increasing number of drop-outs. An
    accepted drop-out should be less than 10.
  • Thus a need for the precise registration of the
    patient address at enrolment and for the tracing
    of patients who fail to show up on the scheduled
    days (Annex III).
  • Those who are excluded because of developing
    exclusion criteria during follow up are not
    included in the calculation of the drop-out rate.
  • The patient is expected to be followed on Days
    1, 2, 3, 7and 14. So drop-out rate will be
    calculated by relating those who are excluded to
    the total patients enrolled.

25
  • Methods of measuring body temperature and body
    weight
  • The patient will be weighed on a reliably
    calibrated scale. The weight is recorded to the
    nearest kg.
  • The body temperature is recorded to one decimal
    point, preferably with electronic thermometer. If
    the axillary temperature is less than 36.0o C,
    the measurement must be repeated.

26
  • Methods of blood examination
  • For microscopic examination, two slides should be
    taken from each patient.
  • Thick and thin blood film should be prepared in
    the same slide.
  • One of the slides should be stained with 10 of
    Giemsa stain and examined for the presence of
    infection. Parasite count will be determined by
    counting the parasite against 200 WBCs. The
    parasite count will be calculated using the
    formula
  • Parasitaemia (per cumm) No. Of parasites X 5000
    / 200
  • The second slide should be kept for further
    reexamination by the control lab of the NMA
  • Presence of gametocyte is not necessary in the
    evaluation of the test.
  • All slides should be kept for reexamination by
    the NMA.

27
  • Classification of the therapeutic response
  • Three categories can be identified
  • ETF (Early treatment failure)
  • Development of danger signs or severe malaria on
    Day 1, 2 or 3 in the presence of parasitaemia.
  • Parasitaemia on Day 3 gt 25 of Day 0.
  • LTF (Late treatment failure)
  • Those are patients not classified as ETF up to
    Day 3 then they developed one of the following
  • Danger signs parasitaemia
  • Unscheduled return due to deterioration
    parasitaemia
  • Presence of parasitaemia in the follow up visits
    on Day 7 or 14.
  • ACR (Adequate clinical response)
  • Patients not classified as ETF or LTF.

28
  • Data Analysis and Interpretation of Test Results
  • Data will be analyzed using SPSS software.
  • ETF, LTF and ACR should be calculated in each
    health facility out of the total patients
    followed.
  • The proportion of treatment failure is the sum of
    ETF and LTF out of the total.

29
Please notice that any treatment failure level
above 25 necessitate changing the Chloroquine as
a first line drug.
30
  • Organization of the Work
  • This work is a collaboration between SMA and the
    NMA and it is fully financed by the NMA / WHO.
  • A State team of 3 4 persons will do the work.
    The team is headed by the Medical Officer in
    charge of the health facility were the test is
    performed and composed of Lab. Technician and a
    Nurse. There is a chance for consultants to join
    this work with a chance of full utilization of
    its results.
  • The Medical Officer is responsible about
    financing and so clearance by the end of the
    period and so he will be paid at last.
  • Regular supervisory visits will be organized by
    NMA concerned staff (At least 3 visits).
  • The equipment required by one study team will be
    procured partially by the NMA building on the
    available in the study site (Annex 5a).
  • The supplies required for patients will be
    procured fully by the NMA (Annex 5b).

31
Endemicity of Malaria in Sudan
High transmission Irrigated Urban Riverine Rural,
high seasonal
About PowerShow.com